964 related articles for article (PubMed ID: 33463388)
21. The effect of combined treatment of bevacizumab and triamcinolone for diabetic macular edema refractory to previous intravitreal mono-injections.
Yolcu Ü; Sobaci G
Int Ophthalmol; 2015 Feb; 35(1):73-9. PubMed ID: 25425105
[TBL] [Abstract][Full Text] [Related]
22. The effects of intravitreal triamcinolone acetonide in diabetic macular edema refractory to anti-VEGF treatment.
Hong IH; Choi W; Han JR
Jpn J Ophthalmol; 2020 Mar; 64(2):196-202. PubMed ID: 31900869
[TBL] [Abstract][Full Text] [Related]
23. Discontinuous to continuous therapy for persistent diabetic macular edema leads to reduction in treatment frequency.
Adams OE; Schechet SA; Hariprasad SM
Eur J Ophthalmol; 2021 Mar; 31(2):612-619. PubMed ID: 31964171
[TBL] [Abstract][Full Text] [Related]
24. Early response to ranibizumab predictive of functional outcome after dexamethasone for unresponsive diabetic macular oedema.
Cicinelli MV; Cavalleri M; Querques L; Rabiolo A; Bandello F; Querques G
Br J Ophthalmol; 2017 Dec; 101(12):1689-1693. PubMed ID: 28432109
[TBL] [Abstract][Full Text] [Related]
25. The additive effect of intravitreal dexamethasone combined with bevacizumab in refractory diabetic macular edema.
Karimi S; Karrabi N; Hassanpour K; Amirabadi A; Daneshvar K; Nouri H; Abtahi SH
J Fr Ophtalmol; 2023 Nov; 46(9):1019-1029. PubMed ID: 37481454
[TBL] [Abstract][Full Text] [Related]
26. Optical coherence tomography biomarkers DROL, PROS, SND, hyperreflective walls of foveal cystoid spaces as predictors of central macular thickness and visual acuity in diabetic macular edema treated with intravitreal ranibizumab.
Sardana A; Singh K; Singh A; Singh VK
Indian J Ophthalmol; 2024 May; 72(5):722-727. PubMed ID: 38648434
[TBL] [Abstract][Full Text] [Related]
27. Comparison of ranibizumab, aflibercept, and dexamethasone implant monotherapy in treatment-naive eyes with diabetic macular edema: A 12-month real-life experience.
Parca O; Cetin EN
Indian J Ophthalmol; 2024 May; 72(Suppl 3):S453-S458. PubMed ID: 38648453
[TBL] [Abstract][Full Text] [Related]
28. Dexamethasone Intravitreal Implant for Chronic Diabetic Macular Edema Resistant to Intravitreal Bevacizumab Treatment.
Totan Y; Güler E; Gürağaç FB
Curr Eye Res; 2016; 41(1):107-13. PubMed ID: 25610946
[TBL] [Abstract][Full Text] [Related]
29. Vitrectomy Combined with Intraoperative Dexamethasone Implant for the Management of Refractory Diabetic Macular Edema.
Kim KT; Jang JW; Kang SW; Chae JB; Cho K; Bae K
Korean J Ophthalmol; 2019 Jun; 33(3):249-258. PubMed ID: 31179656
[TBL] [Abstract][Full Text] [Related]
30. Rapid response to dexamethasone intravitreal implant in diabetic macular edema.
Lo Giudice G; Avarello A; Campana G; Galan A
Eur J Ophthalmol; 2018 Jan; 28(1):74-79. PubMed ID: 28708221
[TBL] [Abstract][Full Text] [Related]
31. Intravitreal injection of a Rho-kinase inhibitor (fasudil) combined with bevacizumab versus bevacizumab monotherapy for diabetic macular oedema: a pilot randomised clinical trial.
Ahmadieh H; Nourinia R; Hafezi-Moghadam A; Sabbaghi H; Nakao S; Zandi S; Yaseri M; Tofighi Z; Akbarian S
Br J Ophthalmol; 2019 Jul; 103(7):922-927. PubMed ID: 30150280
[TBL] [Abstract][Full Text] [Related]
32. Dexamethasone Implants in Diabetic Macular Edema Patients with High Visual Acuity.
Sacconi R; Battaglia Parodi M; Casati S; Lattanzio R; Marchini G; Bandello F
Ophthalmic Res; 2017; 58(3):125-130. PubMed ID: 28704825
[TBL] [Abstract][Full Text] [Related]
33. Baseline SD-OCT characteristics of diabetic macular oedema patterns can predict morphological features and timing of recurrence in patients treated with dexamethasone intravitreal implants.
Eandi CM; De Geronimo D; Giannini D; Polito MS; Tosi GM; Neri G; Le Mer Y; Varano M; Parravano M
Acta Diabetol; 2020 Jul; 57(7):867-874. PubMed ID: 32114643
[TBL] [Abstract][Full Text] [Related]
34. Bevacizumab versus triamcinolone for persistent diabetic macular edema: a randomized clinical trial.
Rodrigues MW; Cardillo JA; Messias A; Siqueira RC; Scott IU; Jorge R
Graefes Arch Clin Exp Ophthalmol; 2020 Mar; 258(3):479-490. PubMed ID: 31873786
[TBL] [Abstract][Full Text] [Related]
35. Three-dimensional analysis of morphologic changes and visual outcomes in diabetic macular edema.
Lee H; Kang KE; Chung H; Kim HC
Jpn J Ophthalmol; 2019 May; 63(3):234-242. PubMed ID: 30783942
[TBL] [Abstract][Full Text] [Related]
36. Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel (DERBI study).
Ehrlich R; Pokroy R; Segal O; Goldstein M; Pollack A; Hanhart J; Barak Y; Kehat R; Shulman S; Vidne O; Abu Ahmad W; Chowers I
Eur J Ophthalmol; 2019 Mar; 29(2):229-233. PubMed ID: 29916263
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of single-dose dexamethasone implantation in patients with persistent diabetic macular edema.
Arıkan Yorgun M; Toklu Y; Mutlu M; Uysal BS; Çakmak HB
Int Ophthalmol; 2016 Aug; 36(4):531-9. PubMed ID: 26644130
[TBL] [Abstract][Full Text] [Related]
38. Intravitreal injection of methotrexate in persistent diabetic macular edema: a 6-month follow-up study.
Falavarjani KG; Golabi S; Modarres M
Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2159-2164. PubMed ID: 27145784
[TBL] [Abstract][Full Text] [Related]
39. Predictive capacity of baseline hyperreflective dots on the intravitreal dexamethasone implant (Ozurdex®) outcomes in diabetic macular edema: a multicenter study.
Fonollosa A; Zarranz-Ventura J; Valverde A; Becerra E; Bernal-Morales C; Pastor-Idoate S; Zapata MA
Graefes Arch Clin Exp Ophthalmol; 2019 Nov; 257(11):2381-2390. PubMed ID: 31451909
[TBL] [Abstract][Full Text] [Related]
40. CHANGES IN SUBFOVEAL CHOROIDAL THICKNESS AFTER INTRAVITREAL DEXAMETHASONE IMPLANT THERAPY FOR DIABETIC MACULAR EDEMA.
Moon KY; Choi SY; Song JH
Retina; 2021 Jun; 41(6):1283-1292. PubMed ID: 33323903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
